Clinical Trial Diversity: ‘How Much More Evidence Do We Need To Move Forward?’

Clinical Trial Diversity: ‘How Much More Evidence Do We Need To Move Forward?’-thegraysheet: FDA seeks research ideas and plans to include demographic subgroup analyses in review templates as some stakeholders call for bolder action to change how companies conduct clinical trials.